Showing results (1-10 of 15) with videos related to
Sort By:
Pageof 2
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|February 26, 2025
Genotyping and treatment issues with 'unusual' HCV 1 subtypesCinzia Caudai, Piera Pierotti, Barbara Rossetti, et al.International Journal of STD & AIDS|August 31, 2017
Reasons for switching ART: Comparison of data collected in 2012-2013 and 2014-2015 in Florence, ItalyFrancesco Maria Fusco, Maria Chiara Burla, Anna Degli Esposti, et al.AIDS (London, England)|April 12, 2005
Distinct patterns of HIV-specific memory T lymphocytes in HIV-exposed uninfected individuals and in HIV-infected patientsMonica Schenal, Sergio Lo Caputo, Francesca Fasano, et al.Journal of Immunology (Baltimore, Md. : 1950)|February 4, 2010
TLR activation pathways in HIV-1-exposed seronegative individualsMara Biasin, Luca Piacentini, Sergio Lo Caputo, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|March 17, 2004
Human alpha defensin in HIV-exposed but uninfected individualsDaria Trabattoni, Sergio Lo Caputo, Giada Maffeis, et al.The Journal of Antimicrobial Chemotherapy|May 27, 2005
Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER CohortCarlo Torti, Franco Maggiolo, Andrea Patroni, et al.Journal of Medical Virology|February 17, 2005
HIV-1 subtypes and circulating recombinant forms (CRFs) from HIV-infected patients residing in two regions of central and southern ItalyLaura Monno, Gaetano Brindicci, Sergio Lo Caputo, et al.Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|November 11, 2005
Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitorsCarlo Torti, Maria Cristina Uccelli, Eugenia Quiros-Roldan, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|March 11, 2003
Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trialFrancesco Mazzotta, Sergio Lo Caputo, Carlo Torti, et al.AIDS Patient Care and Stds|March 3, 2007
Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapyEugenia Quiros-Roldan, Carlo Torti, Giuseppe Lapadula, et al.Pageof 2